Background: Higher plasma CD4 cell counts per mm3 at ART initiation (AI-CD4) improve long-term CD4 responses and survival. Recent data suggest attaining CD4 > 750 is a clinically significant threshold for AIDS-related illness reduction and immune “normalization”. We evaluated the effect of AI-CD4 on chances of achieving CD4 > 750 and mortality risk. Methodology: Among HIV Outpatient Study patients seen during 1996-2012 for three or more years after AI, we analyzed CD4 trajectories and mortality rates per 100 persons-years (MR) by AI-CD4, and the association of AI-CD4 with achieving CD4 > 750 using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 1327 eligible patients followed a median of 7.9 years, > 85% received HAART ≥ 75% of follow-up time, and 64 died. Higher AI-CD4 was associated with increased median peak CD4 (p < 0.001 for trend; see Table). Maximal CD4 response and benefit appeared to plateau at eight years, but differences by AI-CD4 strata persisted (p < 0.001 for trend; see Figure). Lower crude MRs (p = 0.005 for trend) and higher CD4 closest to death (p = 0.013 for trend) were associated with higher AI-CD4. Increases in median CD4 for persons with AI-CD4 < 50 and 50-199 seemed to converge by eight years after AI (< 50% achieved CD4 > 750) whereas patients with AI-CD4 > 350 normalized by eight years (> 80% of patients). In multivariable analyses, higher AI-CD4 was the only factor independently associated with achieving a CD4 > 750 during follow-up through last HOPS contact. Conclusions: Progressively higher AI-CD4 predicted greater long-term CD4 gains, greater chances of achieving CD4 > 750 (“normalization”), increased crude survival rates, and higher CD4 at death. CD4 gains and chances of reaching CD4 >750 peaked at eight years after AI. Most persons with AI-CD4 >350 eventually achieved CD4 normalization while less than half of persons with AI-CD4s < 50 and 50-199 did. AI-CD4 ≥ 500 optimized the likelihood of CD4 normalization. These data confirm the hazards of delayed AI and support AI at CD4 ≥ 500.